Market Overview:
The global immunotoxins market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cancer, technological advancements in immunotoxin therapy, and rising demand for targeted therapies. Based on type, the global immunotoxins market is segmented into anthrax-based toxins, diphtheria toxin (DT) & DT derivatives, pseudomonas exotoxin (PE) & PE derivatives, ribosome-inactivating proteins based immunotoxins, ribonucleases based immunotoxins and others. The anthrax-based toxins segment is expected to account for the largest share of the global Immunotoxin Market by type during the forecast period. This can be attributed to factors such as increasing incidence of biothreats and terrorism across the globe and rising demand for targeted therapies. Based on application,the global ImmunoToxin Market is segmented into solid tumors and leukemias. The solid tumors segment accounted for majority share of this market in 2017and itis projectedto maintain its dominance duringthe forecast period owingto increase incidencesof various typesof cancers such as lung cancer ,breast cancerand colorectalcancer .
Product Definition:
An immunotoxin is a toxin that is specifically targeted against cells of the immune system. This makes them useful for treating diseases caused by excessive activation of the immune system, such as autoimmune diseases or cancer.
Anthrax Based Toxins:
Anthrax based toxins are a group of bacterial products that affect the body's immune system. These products are used in immunotoxins to kill or remove specific cells from the human body. Anthrax based toxins include anthracycline, daunorubicin, doxorubicin, and liposomes among others.
Diphtheria Toxin (DT) & DT Derivatives:
Diphtheria toxin (DT) and its derivatives are used in the manufacturing of immunotoxins. Immunotoxins are used for treatment of diseases caused by immune system malfunctioning such as autoimmune disorders, rheumatoid arthritis, lupus, etc.
Application Insights:
The application segment includes solid tumors, leukemias and lymphomas, and other applications. The growing usage of immunotoxins to treat various types of cancer is expected to be a major factor driving the overall market over the forecast period. Solid tumors accounted for the largest share in 2017 owing to availability of advanced therapeutics that are highly effective against tumor cells. This is also supported by an increasing number of research initiatives undertaken by key companies such as Merck & Co., Inc., Pfizer, Inc., Novo Nordisk A/S, sanofi-aventis ULC regarding new product development for oncology indications.
Rising prevalence rates coupled with increasing awareness about immunotherapy treatment options are anticipated to boost demand from Leukemia & Lymphoma applications during the forecast period.
Regional Analysis:
North America dominated the global immunotoxins market in 2017. This can be attributed to presence of a large number of biopharmaceutical manufacturing entities, which are engaged in producing therapeutics and vaccines for oncology, infectious diseases, and other conditions. The U.S., being one of the most developed nations with high standard of living is expected to remain dominant throughout the forecast period as well.
Key players operating within Asia Pacific include Pfizer Inc.; Merck Group; GlaxoSmithKline plc.; FUJIFILM Diosynth Biotechnologies Co.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for Immunotoxins market. According to World Health Organization (WHO), cancer is the second leading cause of death, accounting for around 9 million deaths in 2015. Immunotoxins are used as an effective treatment for various types of cancers such as colorectal, breast, ovarian, pancreatic and prostate cancers.
- Growing demand for personalized medicine: The growing demand for personalized medicine is another key growth driver for Immunotoxins market. Personalized medicine involves tailoring medical treatment to the individual patient’s needs based on their genetic makeup or lifestyle factors. This approach helps in delivering better outcomes and reducing side effects associated with traditional chemotherapy treatments.
- Technological advancements: The technological advancements in immunotherapy field are fuelling the growth of Immunotoxins market globally .The advent of monoclonal antibodies (mAbs) has revolutionized immunotherapy and led to development of novel targeted therapies such as chimeric antigen receptor T-cell therapy (CAR-T). These technological advancements are helping in improving the efficacy and safety profileof Immunotoxin therapies thereby driving their adoption worldwide .
Scope Of The Report
Report Attributes
Report Details
Report Title
Immunotoxins Market Research Report
By Type
Anthrax Based Toxins, Diphtheria Toxin (DT) & DT Derivatives, Pseudomonas Exotoxin (PE) & PE Derivatives, Ribosome Inactivating Proteins Based Immunotoxins, Ribonucleases based Immunotoxins, Others
By Application
Solid Tumors, Leukemias
By Companies
Biotest, Celldex Therapeutics, Amgen, Genmab, AREVA Med, Bayer HealthCare, Neurocrine Biosciences, Research Corporation Technologies, CuraGen Corporation, Genentech, Biotest
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Immunotoxins Market Report Segments:
The global Immunotoxins market is segmented on the basis of:
Types
Anthrax Based Toxins, Diphtheria Toxin (DT) & DT Derivatives, Pseudomonas Exotoxin (PE) & PE Derivatives, Ribosome Inactivating Proteins Based Immunotoxins, Ribonucleases based Immunotoxins, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Solid Tumors, Leukemias
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biotest
- Celldex Therapeutics
- Amgen
- Genmab
- AREVA Med
- Bayer HealthCare
- Neurocrine Biosciences
- Research Corporation Technologies
- CuraGen Corporation
- Genentech
- Biotest
Highlights of The Immunotoxins Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anthrax Based Toxins
- Diphtheria Toxin (DT) & DT Derivatives
- Pseudomonas Exotoxin (PE) & PE Derivatives
- Ribosome Inactivating Proteins Based Immunotoxins
- Ribonucleases based Immunotoxins
- Others
- By Application:
- Solid Tumors
- Leukemias
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immunotoxins Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Immunotoxins are proteins that can kill or disable cells by attacking their immune system.
Some of the major players in the immunotoxins market are Biotest, Celldex Therapeutics, Amgen, Genmab, AREVA Med, Bayer HealthCare, Neurocrine Biosciences, Research Corporation Technologies, CuraGen Corporation, Genentech, Biotest.
The immunotoxins market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Immunotoxins Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Immunotoxins Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Immunotoxins Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Immunotoxins Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Immunotoxins Market Size & Forecast, 2020-2028
4.5.1 Immunotoxins Market Size and Y-o-Y Growth
4.5.2 Immunotoxins Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Anthrax Based Toxins
5.2.2 Diphtheria Toxin (DT) & DT Derivatives
5.2.3 Pseudomonas Exotoxin (PE) & PE Derivatives
5.2.4 Ribosome Inactivating Proteins Based Immunotoxins
5.2.5 Ribonucleases based Immunotoxins
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Solid Tumors
6.2.2 Leukemias
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Immunotoxins Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Immunotoxins Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Anthrax Based Toxins
9.6.2 Diphtheria Toxin (DT) & DT Derivatives
9.6.3 Pseudomonas Exotoxin (PE) & PE Derivatives
9.6.4 Ribosome Inactivating Proteins Based Immunotoxins
9.6.5 Ribonucleases based Immunotoxins
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Solid Tumors
9.10.2 Leukemias
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Anthrax Based Toxins
10.6.2 Diphtheria Toxin (DT) & DT Derivatives
10.6.3 Pseudomonas Exotoxin (PE) & PE Derivatives
10.6.4 Ribosome Inactivating Proteins Based Immunotoxins
10.6.5 Ribonucleases based Immunotoxins
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Solid Tumors
10.10.2 Leukemias
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Anthrax Based Toxins
11.6.2 Diphtheria Toxin (DT) & DT Derivatives
11.6.3 Pseudomonas Exotoxin (PE) & PE Derivatives
11.6.4 Ribosome Inactivating Proteins Based Immunotoxins
11.6.5 Ribonucleases based Immunotoxins
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Solid Tumors
11.10.2 Leukemias
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Anthrax Based Toxins
12.6.2 Diphtheria Toxin (DT) & DT Derivatives
12.6.3 Pseudomonas Exotoxin (PE) & PE Derivatives
12.6.4 Ribosome Inactivating Proteins Based Immunotoxins
12.6.5 Ribonucleases based Immunotoxins
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Solid Tumors
12.10.2 Leukemias
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Anthrax Based Toxins
13.6.2 Diphtheria Toxin (DT) & DT Derivatives
13.6.3 Pseudomonas Exotoxin (PE) & PE Derivatives
13.6.4 Ribosome Inactivating Proteins Based Immunotoxins
13.6.5 Ribonucleases based Immunotoxins
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Solid Tumors
13.10.2 Leukemias
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Immunotoxins Market: Competitive Dashboard
14.2 Global Immunotoxins Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biotest
14.3.2 Celldex Therapeutics
14.3.3 Amgen
14.3.4 Genmab
14.3.5 AREVA Med
14.3.6 Bayer HealthCare
14.3.7 Neurocrine Biosciences
14.3.8 Research Corporation Technologies
14.3.9 CuraGen Corporation
14.3.10 Genentech
14.3.11 Biotest
